MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Bluebird Bio Inc

Suletud

4.12 0.73

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

3.95

Max

4.16

Põhinäitajad

By Trading Economics

Sissetulek

32M

-29M

Müük

28M

39M

Aktsiakasum

-2.84

Kasumimarginaal

-74.536

Töötajad

248

EBITDA

31M

-9M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+44.23% upside

Turustatistika

By TradingEconomics

Turukapital

-3K

38M

Eelmine avamishind

3.39

Eelmine sulgemishind

4.12

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Bluebird Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

26. sept 2024, 16:08 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Bluebird Bio Inc Prognoos

Hinnasiht

By TipRanks

44.23% tõus

12 kuu keskmine prognoos

Keskmine 6 USD  44.23%

Kõrge 8 USD

Madal 5 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Bluebird Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

1

Osta

3

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.72 / 3.82Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

No Evidence

Pikk perspektiiv

No Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Bluebird Bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.